Explore the paradox of generic drug shortages: why increased competition leads to fragile supply chains. Learn about the economic pressures, regulatory hurdles, and the optimal number of manufacturers needed for stability.
VIEW MOREExplore the complex world of biosimilar manufacturing, from glycosylation challenges and scale-up hurdles to the role of single-use technologies and regulatory requirements.
VIEW MOREExplore the systemic causes of generic drug shortages, from manufacturing failures and API concentration in China and India to the economic pressures of PBMs.
VIEW MOREExplore why generic medications sometimes fail therapeutically, the risks of Narrow Therapeutic Index drugs, and how to spot signs of medication failure.
VIEW MOREExplore why some generic drugs cause therapeutic failure, the risks of the FDA's 80-125% bioequivalence rule, and how to spot medication issues.
VIEW MORELearn how replicate study designs solve the challenge of highly variable drugs in bioequivalence assessments, reducing sample sizes while meeting FDA and EMA standards.
VIEW MORE